The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).
Paul M. Barr
Consultant or Advisory Role - Millennium
Hongli Li
No relevant relationships to disclose
Catherine M Spier
No relevant relationships to disclose
Daruka Mahadevan
No relevant relationships to disclose
Jonathan W. Friedberg
No relevant relationships to disclose
Michael Leo LeBlanc
No relevant relationships to disclose
Mansoor Ul Haq
No relevant relationships to disclose
Christopher Flowers
Consultant or Advisory Role - Millennium (U)
Nina D. Wagner-Johnston
No relevant relationships to disclose
Bruce D. Cheson
No relevant relationships to disclose
Steven M. Horwitz
Consultant or Advisory Role - Millennium
Research Funding - Millennium
Thomas P. Miller
No relevant relationships to disclose
Richard I. Fisher
No relevant relationships to disclose